Key result
Biochemical triple testing reliably excludes monoclonal gammopathy in systemic AL amyloidosis.
Why the study?
Consensus for non-biopsy diagnosis of ATTR-CM requires excluding monoclonal gammopathy using three complementary biochemical tests (SPEP/IFE, UPEP/IFE, and sFLC), yet real-world experience shows frequent omission of one or more assays, motivating an evaluation of the requirement for triple testing.
Does biochemical triple testing (SPEP/IFE, UPEP/IFE, and sFLC assay) improve the exclusion of monoclonal gammopathy in patients evaluated for systemic AL amyloidosis compared to incomplete biochemical testing?
Observational (n=4,949)
No
Does biochemical triple testing (SPEP/IFE, UPEP/IFE, and sFLC assay) improve the exclusion of monoclonal gammopathy in patients evaluated for systemic AL amyloidosis compared to incomplete biochemical testing?
This study evaluates the necessity of performing all three biochemical tests (SPEP/IFE, UPEP/IFE, and sFLC) to reliably exclude monoclonal gammopathy and AL amyloidosis during the non-biopsy diagnostic workup of transthyretin amyloid cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Triple testing may better exclude monoclonal gammopathy in AL amyloidosis; leaves open necessity of all three assays for ATTR-CM workup.
Non-biopsy diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) using technetium bone scintigraphy is well established in patients with heart failure whose echocardiogram or cardiac magnetic resonance scan suggests amyloidosis.1 A critical component of the non-biopsy diagnostic algorithm is exclusion of cardiac AL amyloidosis, which is associated with substantial bone tracer uptake in up to 10% of patients, by excluding the presence of a monoclonal gammopathy. The original validation and current consensus for non-biopsy diagnosis of ATTR-CM require meticulous exclusion of monoclonal gammopathy, performed in parallel with bone scintigraphy, using three complementary methods—serum protein electrophoresis with immunofixation (SPEP/IFE); urine protein electrophoresis with immunofixation (UPEP/IFE); and serum free light chain (sFLC) assay. However, our real-world experience in a national amyloidosis referral centre has highlighted frequent omission of one or more of these assays, most often failure to perform immunofixation in blood and/or urine. To evaluate the requirement to use all three biochemical tests (triple testing), we analysed the results from 4949 untreated patients with proven systemic AL amyloidosis who underwent diagnostic evaluation at the UK National Amyloidosis Centre including a full biochemical screen.
No takes yet. Share an insight, caveat, or question.
Gillmore et al. (2026) conducted an observational in Systemic AL amyloidosis / Transthyretin amyloid cardiomyopathy (ATTR-CM) diagnostic evaluation (n=4,949). Biochemical triple testing (SPEP/IFE, UPEP/IFE, and sFLC assay) vs. Omission of one or more biochemical assays was evaluated on Exclusion of monoclonal gammopathy in systemic AL amyloidosis. Biochemical triple testing (SPEP/IFE, UPEP/IFE, and sFLC) was evaluated in 4,949 untreated patients with proven systemic AL amyloidosis to exclude monoclonal gammopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: